Please ensure Javascript is enabled for purposes of website accessibility

FDA Gives EUA to a Unique COVID-19 Saliva Test

By Eric Volkman – Aug 18, 2020 at 10:19AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The coronavirus diagnostic developed by Yale researchers avoids a number of issues common to current tests.

The Food and Drug Administration has given the nod to a novel new COVID-19 test. The regulator announced Monday that it granted an emergency use authorization (EUA) for SalivaDirect, a diagnostic solution developed by the Yale School of Public Health.

In contrast to most tests currently in use to detect active cases of the SARS-CoV-2 coronavirus, SalivaDirect does not require any kind of swab. Additionally, it does not necessitate a specialized container to hold the harvested sample. As its name implies, it's a saliva test, and the sample can be stored in any type of sterile container.

A sealed, sterile cup for collecting medical samples.

Image source: Getty Images.

"It is also unique because it does not require a separate nucleic acid extraction step," involving additional chemicals, the FDA wrote in its daily round-up of COVID-19 and coronavirus-related news on Monday. "This is significant because the extraction kits used for this step in other tests have been prone to shortages in the past." 

SalivaDirect is the result of research into the coronavirus that indicated it could remain stable in saliva at warm temperatures. The Yale team developed a diagnostic solution around that property. Research indicates that SalivaDirect tests are similar in accuracy and sensitivity to those that use fairly uncomfortable nasopharyngeal swabbing to harvest test samples from within the nose.

In an article on SalivaDirect's receipt of the EUA, YaleNews quoted research team member Chantal Vogels, Ph.D., as saying that with its advantages, "it has the potential to be used on a large scale to help protect public health."

There are various COVID-19 testing products on the market that emphasize convenience and speed. Becton, Dickinson (BDC 1.03%), for one, has a blood testing kit for coronavirus antibodies that it says can deliver results in 15 minutes, while Abbott's (ABT 0.29%) five-minute ID NOW COVID-19 test received its EUA relatively early in the pandemic.

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Abbott Laboratories Stock Quote
Abbott Laboratories
$103.38 (0.29%) $0.30
Belden Stock Quote
$64.80 (1.03%) $0.66

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/05/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.